

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Treatment with vemurafenib can result in the regression of melanoma harboring \_\_\_\_\_.**
  - Activating mutations in the KIT gene
  - BRAF V600E mutations**
  - Both of the above
- 2. Common side effects associated with ipilimumab include \_\_\_\_\_.**
  - Diarrhea
  - Elevations in liver function tests
  - Skin rash
  - Fatigue
  - All of the above**
- 3. \_\_\_\_\_ was approved in 2012 for the treatment of metastatic or recurrent locally advanced basal cell carcinoma.**
  - Vismodegib**
  - Ipilimumab
  - Trametinib
- 4. Anti-PD-1 has demonstrated clinical activity at all doses tested in refractory melanoma.**
  - True**
  - False